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Background: Vulvar carcinomas are rare tumors, and there is limited data regarding molecular alterations. To our
knowledge there are no published studies on c-KIT and squamous cell carcinomas of the vulva (VSCC). Although
there are a significant number of other tumor types which express c-KIT, there remains controversy as to its
relationship to patient outcome. Thus, we wished to investigate such controversial findings to determine the
prognostic importance of c-KIT by evaluating its protein and mRNA expression in VSCCs, correlating these findings
with clinicopathological features and Human Papillomavirus (HPV) infection.
Methods: c-KIT expression was scored by immunohistochemistry (IHC) as positive or negative in 139 formalin-fixed
paraffin-embedded (FFPE) cases of vulvar carcinomas arrayed in a tissue microarray (TMA) using the DAKOW A4502
rabbit polyclonal c-KIT antibody (diluted 1:100). c-KIT mRNA was evaluated by qRT-PCR in 34 frozen samples from
AC Camargo Hospital Biobank (17 tumoral and 17 non-tumoral samples) using TaqMan probes–Applied Biosystems
[Hs00174029_m1]. HPV genotyping was assessed in 103 samples using Linear ArrayW HPV Genotyping Test kit
(Roche Molecular Diagnostics, Basel, Switzerland). All results obtained were correlated with clinical and pathological
data of the patients.
Results: c-KIT protein was positive by immunohistochemistry in 70.5% of the cases and this was associated with a
higher global survival (p = 0.007), a higher recurrence-free survival (p< 0.0001), an absence of associated lesions
(p = 0.001), lymph node metastasis (p = 0.0053), and HPV infection (p = 0.034). Furthermore, c-KIT mRNA quantitation
revealed higher levels of transcripts in normal samples compared to tumor samples (p = 0,0009).
Conclusions: Our findings indicate that those vulvar tumors staining positively for c-KIT present better prognosis.
Thus, positivity of c-KIT as evaluated by IHC may be a good predictor for use of more conservative surgery
techniques and lymph node dissection in vulvar cancer. So part of the essence of our study is to see the possibility
of translating our current results from the bench to the bedside. This will help provide patients a more appropriate,
less mutilating treatment, in order to keep the maximum physical and psychic quality as possible to these women.
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Vulvar carcinoma is a rare malignant tumor that presents
most commonly as a squamous cell carcinoma (90% of
all cases). This neoplasm comprises 3–5% [1-3] of female
genital tract malignant tumors, traditionally being con-
sidered a disease of elderly women (aged between 65 and
75 years) [4,5]. However, in recent decades, its incidence
has risen in younger women, [6] possibly due to the
higher frequency of precursor lesions–vulvar intraepithe-
lial lesions (VINs)–and their association with Human
Papillomavirus (HPV) infection [6,7]. The medical inter-
est in this type of carcinoma was accentuated in the last
decade due to the recognition of the increasing incidence
of the disease. Nevertheless, in spite of the increasing
interest, limited knowledge of molecular alterations in
this type of tumor means that translational research is al-
most absent in this field.
The c-KIT proto-oncogene, also known as SCFR or
CD117 is the v-kit Hardy-Zuckerman 4 feline sarcoma
viral oncogene homolog. Situated at the long arm of
chromosome 4 at 4q11.12, this gene is physiologically
expressed in melanocytes, germ cells [8,9] tissue mast
cells, mammary epithelial cells and sudoriferous glands
and skin basal layers cells [9-11]. During development
and adulthood, c-KIT modulates various processes in-
cluding survival, proliferation, migration and differenti-
ation of hematopoietic cells, germ cells and cells derived
from the neural crest [12,13].
A member of the Tyrosine Kinase Receptor Family III
(β-PDGFR/CSF-1 Family), c-KIT encodes a transmem-
brane receptor and has a specific ligand called SCF
(stem cell factor, also known as c-KIT ligand or mast cell
growth factor) [9]. SCF has two alternatively spliced
forms: whereas the soluble form immediately stimulates
tyrosine kinase activity, the membrane-bound form pro-
duces long-term effects, increasing the stability of the re-
ceptor and preventing its rapid downregulation [9]. The
interaction between SCF and c-KIT receptor activates
the tyrosine kinase function which, in turn, induces
phosphorylation of various cellular proteins and activa-
tion of a number of cascades, among them via RAS,
PI3K and PLCγ, as shown on Figure 1.
Various types of neoplasms express c-KIT. In GISTs, for
example, this expression is very common [14]. Also,
angioleiomyolipomas [15], small-cell lung carcinomas,
seminomas/dysgerminomas [10], and leukemias [9,16]
frequently express c-KIT. In many tumor types, this re-
ceptor is associated with malignancy. In gastrointestinal
stromal tumors, myeloid leukemias and mast cell disor-
ders, for example, c-KIT gene gain-of-function mutations
result in constitutive tyrosine kinase activity and are con-
sidered to play a central role in oncogenesis and sustained
tumor growth [17,18]. Coexpression of c-KIT and its lig-
and in small-cell lung cancer, for example, appears toresult in an autocrine growth loop sustaining tumor cell
proliferation [9,19]. On the other hand, a markedly better
outcome has already been demonstrated in tumors that
expressed c-KIT compared with those that did not, such
as neuroblastomas [9], nasopharyngeal carcinomas [20]
and multiple myeloma [21].
Such controversial findings lead us to investigate the role
of this receptor in vulvar carcinomas, as the literature is
very limited in this respect and, to our knowledge, no study
has been published regarding c-KIT evaluation in squa-
mous cell carcinomas of the vulva (VSCC). For this reason,
the present study was designed to evaluate whether c-KIT
predicts patient’s outcome in VSCCs and, if so, if this mar-
ker can be considered as an efficient prognostic factor. We
assessed mRNA expression of c-KIT and its protein prod-
uct in vulvar squamous cell carcinomas and correlated
these data with clinicopathological features and with the
presence of HPV infection, in order to determine the prog-
nostic importance of this receptor in vulvar cancer.
Methods
Patients and samples
This was a retrospective study of 139 formalin-fixed
paraffin-embedded (FFPE) tumor tissue samples selected
retrospectively and randomly of patients who had surgi-
cal intervention–biopsy or vulvectomy–selected from the
Anatomic Pathology Department of A.C. Camargo Hos-
pital, São Paulo, Brazil between the years 1979 to 2006.
According to standardized protocols (used in this insti-
tution) all tumor specimens obtained from surgery or bi-
opsy are always maintained in 10% buffered formalin for
8 hours and then paraffin-embedded and enclosed in a
labeled cassette for storage in the archives of the Ana-
tomic Pathology Department. For our study, diagnosis
was confirmed and cases were re-classified by an experi-
enced pathologist. All cases were arrayed in duplicates by
selecting representative areas of tumor arranged in a tis-
sue microarray (TMA), using the tissue arrayer (Beecher
Instruments, Silver Springs, Maryland). In situ carcin-
omas, patients who received neoadjuvant treatment
(chemotherapy or radiotherapy) and those tumors whose
paraffin blocks were unavailable or contained insufficient
material were excluded from the study. Furthermore, 17
frozen tissue samples of surgically removed tumors and
17 non-tumor samples adjacent to the tumor stored in
the A.C. Camargo Hospital Biobank, were used to assess
mRNA expression by qRT-PCR. This work has been
approved by the Ethics Committee of our institution (AC
Camargo Research Ethics Committee–Number 1379/10)
and is in compliance with the Helsinki Declaration.
Immunohistochemistry
IHC was performed in TMA section using the auto-
mated Ventana BenchmarkW platform (Ventana Medical
Figure 1 Main pathways activated by the tyrosine-kinase receptor c-KIT and its effects on carcinogenesis. KIT dimerization occurs from
the SCF (yellow) coupling, which leads to phosphorylation of the tyrosine kinase domains (shown with red dots along the intracellular portions of
receptors), which triggers the coupling and recruitment of several intracellular proteins that in turn, activate the three routes shown in colors
(MAPK, PLCγ and PI3K pathways in purple, red and orange, respectively). This process culminates in cellular activities highlighted in rectangles.
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polyclonal c-KIT antibody diluted 1:100 was used; posi-
tive and negative controls were included in the batch.
Assessment of immunoreactivity
The immunoreactivity of c-KIT protein was evaluated
on the cell membrane and/or cytoplasm, graded as pre-
viously described by other authors [22], based on two
parameters: intensity of staining and percentage of
stained cells. The intensity of staining was scored as
0 = negative, 1 = weak staining, 2 = moderate staining,
3 = strong staining. The percentage of labeled cells was
scored as (a) sporadically stained = less than 10% of
positive cells, (b) focal staining = amount greater than or
equal to 11% and less than 50% of the stained cells, and
(c) diffuse = more than 50% of cells positively stained.
Positivity cut off was established with staining intensity
of 2 + or 3 + combined with focal or diffuse pattern,
respectively.
Quantitative RT-PCR
Total RNA was extracted from 17 frozen tissue samples
of surgically removed tumors and 17 non-tumor samples
(adjacent to the tumor) using the RNeasy Mini Kit
(QIAGEN, Austin, TX, USA), according to themanufacturer’s protocol. cDNA was synthesized from
total RNA using the High-Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, Foster City, CA,
USA). Quantitative RT-PCR was performed in Applied
Biosystems 7900HT Fast Real-Time PCR System (Ap-
plied Biosystems, Foster City, CA, USA). A set of pri-
mers and TaqMan probes for c-KIT were purchased
from Applied Biosystems [Hs00174029_m1]. A pool of
normal skin tissue was used as the control sample and
HPRT was elected as the reference gene. The relative
quantification (RQ) method was applied to determine
the gene expression levels. Values of RQ within the
range (RQ ± 2SD) in the corresponding referent group
were accepted as normal.
HPV DNA detection and genotyping
DNA was obtained and isolated from 139 formalin FFPE
tissues following the supplier’s recommendations for
QIAamp DNA FFPE Tissue Kit, based on the QIAamp
method (QIAGEN, Valencia, CA, USA). One hundred
and three samples demonstrated satisfactory quality of
the DNA obtained and were used for the HPV genotyp-
ing using the Linear ArrayW HPV Genotyping Test kit
(Roche Molecular Diagnostics, Basel, Switzerland). The
results of the hybridization were assessed visually by
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greater than 0.2 were classified as positive for either
HPV and/or β-globin presence.
Statistical analysis
The significance of the associations between IHC results
with histological features and clinical data was analyzed
by Fisher’s exact test adopting p< 0.05 as the significance
level. Kaplan-Meier analysis was performed for survival
curves using the log-rank-test and the date of diagnosis
to the death or last follow up. Software SPSS for Win-
dows (version 13.0) was used for statistical analyzes.
Results
Demographic, anatomopathological and clinical data of
the patients
The mean age of the onset of the disease was 69 years
(SD = 12), ranging from 15–98 years and median age of
onset was 71 years. Most patients ranged in age between
70 and 80 years (54.67%). Regarding demographics, the
majority of patients were white (86.3%), married
(50.30%), and almost all women (78.37%) were illiterate
or had incomplete primary education.
Most tumors were classified as well-differentiated Squa-
mous Cell Carcinomas (SCC)–SCC1 (43.88%), followed
by SCC 2 (33.81%), SCC 3 (10.07%), basaloid carcinomas
(9.35%) and verrucous and sarcomatoid carcinomas
(1.44% each). In relation to the depth of invasion, 20.78%
infiltrated the superficial dermis, 54.55% of the tumors
infiltrated the deep dermis and 24.68% infiltrated the sub-
cutaneous tissue. A moderate inflammatory infiltrate was
most commonly observed (62.6%). Most tumors showed
no vascular invasion (84.89%) or perineural invasion
(89.21%). No lymph nodes metastases were observed in
71.94% of cases which had had a lymphadenectomy. How-
ever, 28.06% had some degree of lymph node involvement.
Among our series, most of tumors were classified as FIGO
staging IB (58.91%) and IIIB (19.37%), according to the
staging proposed by the International Federation of
Gynecology and Obstetrics (FIGO).
Treatment complications were found in 54.5% of
women, and recurrence was observed in 38.58% of cases:
local and nodal recurrences were more frequent (38.78%
and 24.49% of all types of recurrence, respectively).
Among women with any recurrence, 65.3% died of this
cancer. In relation to the overall status of the patients,
41.30% were alive without cancer, 33.33% died of the dis-
ease, 13.04% died of other causes, 7.24% were alive with
disease, and 5.07% died of unspecified causes. Global
survival for all patients showed a median of 86 months.
c-KIT immunostaining
Positivity of c-KIT by immunohistochemistry was
observed in the cell membrane and/or in the cytoplasmof 70.5% of the cases (98/139 cases). Almost 24% of the
cases were negative and 5.04% (7 cases) were not evalu-
ated as the TMA spot was missing. Positivity and nega-
tivity of c-KIT are illustrated in Figure 2.
Protein expression and clinicopathological features
Associations between c-KIT expression and clinico-
pathological features and HPV infection are listed in
Table 1. 68% of c-KIT positive tumors did not show any
type of associated lesions, such as in situ carcinoma,
VINs, lichen sclerosus or vulvar acanthosis (p = 0.0001).
c-KIT positive cases were associated with an absence of,
or only one, lymph node involvement (p = 0.0053) when
compared to c-KIT negative cases, which were asso-
ciated with two or more lymph-node metastasis.
c-KIT expression and HPV
HPV infection was detected in 58.25% of the samples.
Among those, HPV16 (44.18%) and HPV33 (27.9%) were
the most commonly found. 77% of the patients pre-
sented only one infecting type of the virus. However,
mutual infection by two or three types of HPV was
observed in 11.62% of cases, each (Table 1). There was a
significant agreement between c-KIT positivity and HPV
infection (p = 0.034).
c-KIT expression and patient’s survival
Our results showed a better 5 year global survival
(p = 0.007) and recurrence-free survival (p< 0.0001) for
patients with c-KIT positive tumors compared to those
whose tumors were negative, as shown in Figure 3.
c-KIT mRNA expression
c-KIT gene expression quantitated by qRT-PCR revealed
higher levels of mRNA transcripts in normal samples
(average relative quantification–RQ: 3.21) when com-
pared to tumor samples (average relative quantification–
RQ: 0.54), as shown on Figure 4 (p = 0.0009). These
observations could not be compared with immunohisto-
chemistry and clinicopathological variables as the sample
size was too small to perform statistical tests.
When evaluated by IHC in a smaller set of whole sec-
tion tumors (10 cases), using IHC in whole section
tumors, the protein product was also higher in normal
areas as seen in Figure 4B when compared to tumor
areas from the same (Figure 4B and C).
Discussion
As vulvar carcinoma is a relatively rare cancer, very little
is known about novel biomarkers with prognostic or
predictive roles, although initial efforts are being made.
Patients and health services must be made aware of the
importance of gynecological evaluation and education
policies should be strengthened to increase awareness
Figure 2 c-KIT immunostaining in vulvar carcinomas: evaluation of immunoreactivity at the membrane and/or cytoplasm (200x
magnification). (A) Graphical plot of c-kit immunostaining results by IHC: the number of samples is shown in vertical axis, and the staining in the
horizontal axis; (B) and (C): Negative immunostaining for c-KIT; (D) Positive immunostaining for c-KIT in the membrane (arrow); (E) Positive
immunostaining for c-KIT in the membrane and cytoplasm (arrows).
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cer and HPV infection. In our study, we wished to deter-
mine the prognostic importance of c-KIT, a novel
prognostic and predictive biomarker for other neo-
plasms, by evaluating its protein and mRNA expression
in vulvar squamous cell carcinomas and correlating its
positivity with clinicopathological features and HPV
infection.
Our results showed a c-KIT protein positivity by IHC
in 70.5% of cases, which was associated with a higher
recurrence-free and global survival, an absence ofTable 1 Evaluation of histopathological characteristics,
clinical data and HPV infection of the patients in relation
to c-KIT immunostaining
c-KIT immunostaining
Variables Category Staining Total P value
Negativea Positiveb
n (%) n (%)
HPV Negative 17 (30) 6 (15) 24 0.034
Positive 40 (70) 34 (85) 75
Nodal metastasis No 9 (47) 35 (69) 44 0.0053
Yes 10 (53) 16 (31) 26
Associated lesions No 26 (84) 62 (68) 88 0.0001
Yes 5 (16) 29 (32) 34
a. Negative: no immunostaining.
b. Positive: membrane and/or cytoplasm staining.associated lesions or lymph node metastasis and HPV
infection, suggesting an important role of this receptor
in vulvar carcinoma as a good prognosis marker. Fur-
thermore, c-KIT mRNA quantitation revealed higher
transcription levels in normal samples than tumor sam-
ples. Thus, this receptor may have potential as a good
prognostic marker in vulvar carcinomas.
Proto-oncogene c-KIT encoded tyrosine kinase
appears to have an important role in carcinogenesis of
various tumors, including gastrointestinal stromal tu-
mors (GIST), melanomas, seminomas, glioblastomas, breast
cancer and acute myeloid leukemias (AML) [17, 18].
The c-KIT/SCF system seems to be also involved in car-
cinogenesis of the female genital tract [23]. In most
tumors, progressive decrease in c-KIT expression is re-
ported as long as the tumor grows and invades [23, 24],
being positive in normal tissues and decreased in tumor
cells. Such data corroborates with our study, since sig-
nificantly higher expression of c-KIT mRNA was observed
in normal tissue when compared to tumor microdis-
sected samples.
In this study, high IHC expression of c-KIT receptor
was similar to that described by Eroglu et al. (2008) [25]
who found a strong diffuse high expression of protein in
the cytoplasm and/or membrane of vulvar epithelioid
sarcoma cells. The frequent finding of IHC cytoplasmic
staining among our cases suggests an internalization of
the receptor after its binding to SCF, which may indicate
Figure 3 Kaplan-Meier Global and Recurrence-free survival curves for c-KIT staining. c-KIT positivity correlated with better global survival
(p = 0.007) (A) and recurrence-free survival (p< 0.0001) (B) when compared to negative stained tumors (shown in blue lines).
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the result of a rapid turnover of the protein when no
longer located in the membrane [9,26].
Longer global and disease free survivals were observed
in our patients with positive expression of c-KIT. Similar
findings have also been shown by other authors in neu-
roblastomas [9], nasopharyngeal carcinomas [20] and
multiple myeloma [21]. These authors reported that the
expression of c-KIT and a better prognosis is an “unex-
pected” finding since, in several tumor types, c-KIT is
associated with malignancy [9] as a result of constitu-
tively turned on tyrosine kinase and, in the case of both
expression of c-KIT and its ligand SCF, as a result of
self-support from an autocrine tumor growth feedback
loop [9,19]. Bataille et al (2008) [21] found a 93% sur-
vival in 4 years for patients with c-KIT positive multiple
myeloma versus 64% for c-KIT negative. Similarly, our
data show overall survival of 72% for c-KIT positive and
50% for c-KIT negative. Also, a correlation between c-KIT
positivity and better recurrence-free survival was ob-
served. Both vulvar skin bridge recurrences and primary
tumor site recurrences have been shown in the literature
as strong predictors for cancer-related death [27] and,
therefore, this supports the utility of this marker as a
powerful predictor for tumor recurrence.
The fact that c-KIT exerts divergent functions depend-
ing on its modulation by environmental factors, its inter-
actions with several different intracellular effectors
pathways and alternative splicing of its mRNA, may ac-
count for the differences in function found in different
tumors [9,28,29]. Studies done in vitro and in vivo in
melanoma cells have shown that exposure of c-KIT posi-
tive cells to SCF triggers apoptosis, which does not hap-
pen in c-KIT negative cells or in normal melanocytes.Since SCF is normally produced by keratinocytes and
other dermal cells, loss of expression of c-KIT may allow
malignant melanoma cells to escape c-KIT/SCF mediated
apoptosis, contributing to growth and tumor metastasis
[29, 30].
The most important clinical prognostic factor in vulvar
cancer is the lymph node status, which is a part of surgi-
copathological staging by FIGO [31]. In this sense, it is
important to note that a grouping strategy regarding
lymph node involvement was made to allow a biologic-
ally rational insight of the statistical analysis. Our results
show that c-KIT positive cases were associated with ab-
sence or involvement of only one lymph node (p = 0.0053)
when compared to c-KIT negative cases, which were
associated with two or more lymph-node metastasis.
This grouping strategy was used by Holschneider and
Berek [32] and states that patients with no nodes or only
one microscopically involved have a comparable progno-
sis. The association between positive staining for c-KIT
and absence of lymph node metastases, absence of asso-
ciated lesions, and higher survival rates indicates that
this is a marker of good prognosis in vulvar cancer. Pos-
sibly, in tumors with positive staining for c-KIT, more
conservative surgery with less mutilation should be eval-
uated in order to provide a better psychosocial quality of
life of these women. These psychosocial issues are widely
described in the literature as one of the most important
concerns especially among younger patients, regarding
complications of therapy [31]. Fear, distorted body image
and depression, are the most frequent symptoms men-
tioned in the literature, in this regard [31]. Implementing
translational research findings including molecular mark-
er evaluation, such as c-KIT, could be helpful in develop-
ing a more personalized approach to the treatment of
Figure 4 c-KIT mRNA and protein expression in vulvar
carcinomas. (A) c-KIT mRNA expression evaluated by qRT-PCR using
Relative Quantification (RQ) values (shown vertical axis). Normal
samples transcript expression is shown significantly higher than
tumor expression (p = 0.0009); c-KIT protein expression assessed by
immunohistochemistry showing stronger immunostaining in normal
area (B, arrows: normal epithelium, star: stroma) than in tumor area
(C, arrow: invasive squamous cell carcinoma with irregular infiltrating
borders, star: stroma).
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prognostic factor for vulvar carcinoma.
A relationship between positive expression of c-KIT
and the presence of HPV was demonstrated in this
study, although there is no data in the literature suggest-
ing this. We hypothesize that (1) the locus of c-KIT gene
may be a fragile site yet unknown for integration of
HPV; or (2) abnormalities in the regulation of this genemay be accelerating the process of carcinogenesis in co-
operation with the viral infection. Besides, the positive
correlation between c-KIT expression and HPV rein-
forces the good prognosis of these tumors, as tumors
associated with HPV, which is considered an independ-
ent predictor of better survival [33].
Regarding treatment and further predictive values of
c-KIT, the positive overexpression of this receptor was
found to be associated with a better global and disease
free survival in patients with vulvar cancer. For this rea-
son, contrary to the situation found in other c-KIT posi-
tive tumors, the use of a c-KIT inhibitor such as
GleevecW may be inappropriate in vulvar cancer. How-
ever, a better understanding of the molecular regulatory
mechanisms of c-KIT may, in the future, play a role in
the development of targeted therapies in order to inhibit
or modulate the signaling pathways triggered by this
receptor.
Vulvar carcinoma is a rare disease, and thus our study
was limited in size. We also encountered problems with
lack of clinical information, which reduced numbers fur-
ther. Scarcity of publications also leads us to a more
speculative discussion and comparison with other
neoplasms.
The association between positive staining for c-KIT
and absence of lymph node metastases, absence of asso-
ciated lesions, and higher survival rates indicates that
this is a marker of good prognosis in vulvar cancer. Pos-
sibly, in tumors with positive staining for c-KIT, more
conservative surgery with less mutilation should be eval-
uated in order to provide a better psychosocial quality of
life of these women [31]. Fear, distorted body image and
depression, are the most frequent symptoms mentioned
in the literature regarding the psychosocial quality of life
of these patients [31] and could be relieved if more per-
sonalized medicine through molecular markers evalu-
ation was used. Thus, molecular marker evaluation (c-
KIT positivity), could be used as a prognostic factor for
vulvar carcinoma, implementing translational research
findings into part of a more personalized approach to
each individual patient and their therapy.
Conclusions
The literature has already shown the important role of
the tyrosine kinase encoded by c-KIT in carcinogenesis
of various tumors. Our study suggests its important role
in vulvar carcinoma as a marker for good prognosis.
This implies that the most aggressive vulvar cancer cases
may not benefit from c-KIT targeted therapies as they
already have low c-KIT expression. The high expression
of this receptor among our cases suggests that, a better
understanding of the molecular mechanisms involved
in patients with c-KIT positivity will be required to se-
lect a more appropriate type of target therapy. In
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be possible after IHC evaluation of c-KIT in vulvar can-
cer, bringing results from bench to the bedside in order
to provide a better psychosocial quality of life for the
women.
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